[{"orgOrder":0,"company":"The First Affiliated Hospital of Zhengzhou University","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"The First Affiliated Hospital of Zhengzhou University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital of Zhengzhou University \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"The First Affiliated Hospital of Zhengzhou University \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Konkuk University Medical Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Konkuk University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Konkuk University Medical Center \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Konkuk University Medical Center \/ GSK"},{"orgOrder":0,"company":"Basque Health Service","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Basque Health Service","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basque Health Service \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basque Health Service \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Medasense Biometrics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Medasense Biometrics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medasense Biometrics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medasense Biometrics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Kathirvel Subramaniam","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Kathirvel Subramaniam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kathirvel Subramaniam \/ Viatris","highestDevelopmentStatusID":"11","companyTruncated":"Kathirvel Subramaniam \/ Viatris"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Al-Azhar University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Al-Azhar University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Al-Azhar University"}]

Find Clinical Drug Pipeline Developments & Deals for Remifentanil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Egymedicalpedia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Egymedicalpedia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 04, 2024

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Al-Azhar University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The First Affiliated Hospital of Zhengzhou University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          The First Affiliated Hospital of Zhengzhou University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Critical Illness.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2015

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Yichang Humanwell Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 11, 2015

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Kathirvel Subramaniam

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Kathirvel Subramaniam

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 28, 2015

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Viatris

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anesthesia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 28, 2013

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tachycardia, Ventricular.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 17, 2013

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Medasense Biometrics

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Medasense Biometrics

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of General Surgery.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 07, 2013

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Konkuk University Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Konkuk University Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 26, 2012

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Basque Health Service

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Basque Health Service

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pregnancy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2010

                          Lead Product(s) : Remifentanil

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank